Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD)/phase II recommended dose and describe toxicities related to PD-0332991 (palbociclib isethionate) in children with retinoblastoma protein 1 (Rb1) positive recurrent, progressive or refractory primary central nervous system (CNS) tumors. II. To determine plasma pharmacokinetics of PD-0332991 in children with Rb1positive recurrent, progressive or refractory primary CNS tumors. SECONDARY OBJECTIVES: I. To record preliminary evidence of efficacy of PD-0332991 in children with recurrent CNS tumors. II. To evaluate cyclin-dependent kinase (CDK)4/6, cyclin D1-3, Ink4a-ARF copy-number variations in available tumor tissue by array comparative, genomic hybridization (aCGH). III. To explore the potential relationships between the pharmacokinetics of PD-0332991 and pharmacodynamic response (e.g. percentage change in absolute neutrophil count [ANC], platelet counts). IV. To explore the pharmacogenetic polymorphisms in PD-0332991 metabolizing enzymes and transporters and relate these polymorphisms to PD-0332991 pharmacokinetics. OUTLINE: This is a dose-escalation study. Patients receive palbociclib isethionate orally (PO) once daily (QD) on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days. ;


Study Design


Related Conditions & MeSH terms

  • Astrocytoma
  • Central Nervous System Neoplasms
  • Childhood Choroid Plexus Tumor
  • Childhood Ependymoblastoma
  • Childhood Grade III Meningioma
  • Childhood High-grade Cerebellar Astrocytoma
  • Childhood High-grade Cerebral Astrocytoma
  • Childhood Medulloepithelioma
  • Choroid Plexus Neoplasms
  • Glioblastoma
  • Gliosarcoma
  • Medulloblastoma
  • Meningioma
  • Neoplasms
  • Neoplasms, Neuroepithelial
  • Nervous System Neoplasms
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Oligodendroglioma
  • Pinealoma
  • Recurrent Childhood Anaplastic Astrocytoma
  • Recurrent Childhood Anaplastic Oligoastrocytoma
  • Recurrent Childhood Anaplastic Oligodendroglioma
  • Recurrent Childhood Brain Stem Glioma
  • Recurrent Childhood Cerebellar Astrocytoma
  • Recurrent Childhood Cerebral Astrocytoma
  • Recurrent Childhood Giant Cell Glioblastoma
  • Recurrent Childhood Glioblastoma
  • Recurrent Childhood Gliomatosis Cerebri
  • Recurrent Childhood Gliosarcoma
  • Recurrent Childhood Medulloblastoma
  • Recurrent Childhood Pineoblastoma
  • Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor

NCT number NCT02255461
Study type Interventional
Source Pediatric Brain Tumor Consortium
Contact
Status Terminated
Phase Phase 1
Start date December 8, 2014
Completion date February 25, 2019

See also
  Status Clinical Trial Phase
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00095940 - Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Phase 1/Phase 2
Completed NCT00052780 - Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Phase 1
Completed NCT00004078 - Irinotecan in Treating Children With Refractory Solid Tumors Phase 2
Completed NCT01239316 - Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Phase 2
Completed NCT00100880 - Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Phase 1
Completed NCT00070525 - Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Phase 2
Terminated NCT01088763 - Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00326664 - AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Phase 1
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Completed NCT02271711 - Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors Phase 1
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT02444546 - Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors Phase 1
Completed NCT00363272 - Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Phase 1
Completed NCT00946335 - ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Phase 1
Completed NCT00063973 - Cilengitide in Treating Children With Refractory Primary Brain Tumors Phase 1
Completed NCT00822458 - GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment Phase 1
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Terminated NCT02684071 - Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Phase 2